ArriVent BioPharma Advances Lung Cancer & GI Oncology Programs with Promising Data & New Leadership

November 10, 2025 – ArriVent BioPharma, Inc. is making significant progress in the fight against cancer, reporting encouraging clinical data for its lead drug candidate, firmonertinib, in EGFR-mutated non-small cell lung cancer (NSCLC), and expanding its pipeline with an antibody-drug conjugate (ADC) targeting gastrointestinal malignancies. The company, which recently appointed a new Chief Commercial Officer, appears poised for a period of growth as it advances multiple programs toward potential commercialization.

Positive Data in EGFR-Mutated NSCLC Fuels Hope

ArriVent is focused on addressing unmet needs in NSCLC, particularly in patients with uncommon EGFR mutations like PACC (P-loop and Alpha C-helix Compressing). Traditional EGFR tyrosine kinase inhibitors (TKIs) often fail in these patients, creating a critical need for new treatment options. Preliminary data from ongoing clinical trials of firmonertinib, a third-generation EGFR TKI, are demonstrating promising results in this challenging population.

“The initial data are very encouraging,” said one anonymous oncology expert familiar with the trial data. “We’re seeing responses in patients who have previously failed multiple lines of therapy. This could represent a meaningful advance for a patient group with limited options.”

The company is currently enrolling patients in a pivotal Phase 3 trial, comparing firmonertinib to investigator’s choice of osimertinib or afatinib. Analysts predict that positive data from this trial could position firmonertinib as a best-in-class therapy for EGFR-mutated NSCLC, potentially capturing a significant share of the multi-billion dollar market.

Expanding into Gastrointestinal Oncology with Innovative ADC

Beyond lung cancer, ArriVent is also making inroads into gastrointestinal oncology with its ADC program, ARR-217. This innovative therapy targets CDH17, a protein highly expressed in various gastrointestinal cancers, including gastric, colorectal, pancreatic, and bile duct cancers. The ADC delivers a potent cytotoxic payload directly to cancer cells, minimizing systemic toxicity.

“CDH17 is an attractive target because it’s predominantly expressed on gastrointestinal cancer cells but is often inaccessible, making it a good target for an ADC,